Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

By sjmartinez • July 18, 2023

Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. PMID: 37460276.

Tags: covid-19, Nebuliser therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, Hsieh CY, Ghi MG, Vaz[...]

Characterising the protective vasodilatory effects of hypobaric hypoxia on the neurovascular coupling response

Leacy JK, Burns DP, Jendzjowsky NG, Braun C, Herrington BA, Wilson RJ, Vermeulen TD, Foster GE, Rosenberg AJ, Anderson GK, Rickards CA, Lucking EF, O'Halloran[...]

Racial and Ethnic Disparities in Referral to Outpatient Heart Failure Management at Hospital Discharge: A Get With The Guidelines Analysis

Wang M, He X, Crawford K, Ko YA, Dickert NW, Patel SA, Pandey A, DeFilippis EM, Breathett K, Cogswell R, Yancy CW, Fonarow GC, Morris[...]